ASGE Recognized Industry Associate (ARIA) Training Program for Regeneron and Sanofi | August 2024-Pathophysiology & Current Treatment of EoE

Video Transcription

Video Summary

The video transcript details a comprehensive lecture on the pathophysiology and treatment of Eosinophilic Esophagitis (EOE). The presenter, addressing a mixed audience including immunologists, covers various treatment endpoints, standard therapies, and the importance of understanding pathophysiology, especially in relation to biologic therapies. The case study centers on a 20-year-old college athlete diagnosed with EOE since grade school, highlighting treatment challenges and steps. Treatment strategies discussed include drug therapy (PPIs and steroids like budesonide), dietary changes, and endoscopic dilation. The effectiveness of different medications and the necessity of patient compliance and proper dosage instructions are emphasized. Guidelines from the AGA and FDA approvals, such as budesonide for EOE, are also mentioned. Additionally, the lecture explores why repeat endoscopies and biopsies are critical for assessing treatment efficacy and the role of targeted biologic therapies options like dupilumab. It stresses EOE’s chronic nature and the importance of maintenance therapy to control inflammatory and structural damage over time while aligning treatment plans with patient preferences and adherence.

Asset Subtitle

Diana Snyder, MD

Keywords

Eosinophilic Esophagitis

pathophysiology

treatment endpoints

biologic therapies

PPIs

budesonide

dietary changes

endoscopic dilation

dupilumab